{"id":"tak-771","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL5897630","moleculeType":null,"molecularWeight":"535.53"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TAK-771 selectively targets FGFR4, a receptor frequently activated in hepatocellular carcinoma through FGF19 autocrine signaling, which drives tumor cell proliferation and survival. By inhibiting FGFR4 kinase activity, the drug suppresses downstream oncogenic pathways including MAPK and PI3K/AKT signaling. This selective approach aims to provide anti-tumor activity while potentially minimizing off-target toxicities associated with pan-FGFR inhibition.","oneSentence":"TAK-771 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:17.763Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), FGFR4-driven"}]},"trialDetails":[{"nctId":"NCT05084053","phase":"PHASE3","title":"A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2022-01-19","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN)","enrollment":26},{"nctId":"NCT05513586","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-09-13","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":15},{"nctId":"NCT05150340","phase":"PHASE3","title":"A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-01-24","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase"],"phase":"phase_3","status":"active","brandName":"TAK-771","genericName":"TAK-771","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-771 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma. Used for Hepatocellular carcinoma (HCC), FGFR4-driven.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}